• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 3, 2014

View Archived Issues

Edison Pharmaceuticals, Dainippon bolster their partnership in potential $4.3B deal

Less than a year into their drug development partnership, privately held Edison Pharmaceuticals Inc. and Japan’s Dainippon Sumitomo Pharma Co. Ltd. (DSP) bulked up the deal, inking a potential $4.295 billion strategic alliance that vastly expands their pursuit of drugs targeting cellular energy metabolism. Read More

Rhythm, no blues: Vanda sleep therapy wins FDA clearance

Vanda Pharmaceuticals Inc.’s sales force for Hetlioz (tasimelteon) is “intact and in launch mode,” said CEO Mihael Polymeropoulos, after Friday’s approval of the selective melatonin receptor agonist for non-24-hour wake-sleep disorder (non-24). Read More

The biotech IPO window widens – three more firms step through

Throw the predictions out of the window. Any thoughts that the number of biotech initial public offerings (IPO) would slow down anytime soon will surely be dispelled with the successful completion of five offerings. Cara Therapeutics Inc., Trevena Inc. and Ultragenyx Pharmaceutical Inc. have followed Dicerna Pharmaceuticals Inc. and Celladon Corp., which priced their IPOs Thursday. Read More

Cancer vaccine works, if you know where to look

Scientists reported recently that a therapeutic vaccine for precancerous cervical lesions induced strong immune responses. But those immune responses were only apparent when the team analyzed the cervical tissue itself, not when they used the standard approach of looking for activated immune cells in the blood. Read More

Late-stage evolution for Intra-Cellular; firm raises $107M, jumps to Nasdaq

With an eye toward launching a Phase III program in schizophrenia later this year, Intra-Cellular Therapies Inc. priced a $107.5 million public offering after market close Thursday, selling about 6.1 million shares priced at $17.50 apiece. Read More

Clinic roundup

Enanta Pharmaceuticals Inc., of Watertown, Mass., reported results from the PEARL-II, PEARL-III, PEARL-IV and TURQUOISE-II studies, which are the remaining Phase III studies of the six Phase III registrational studies being conducted by Chicago-based Abbvie Inc. for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection using a regimen containing Enanta’s lead protease inhibitor ABT-450. Read More

Stock Movers

Read More

Pharma: Other news to note

Actavis plc, of Dublin, said it expects 2013 non-GAAP earnings per diluted share to be modestly above the high end of its previous forecast. Read More

Appointments and advancements

Incyte Corp., of Wilmington, Del., appointed Hervé Hoppenot president and CEO. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from the University of Minnesota have demonstrated that even in patients with undetectable levels of HIV in their blood – which is the goal and the usual consequence of highly active antiretroviral therapy (HAART) – the virus persists in replicating in the lymph system. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe